Arcoxia

Arcoxia

A brand name for ETORICOXIB.
References in periodicals archive ?
Esse anti-inflamatorio foi ingerido por 3 dias porque o atleta estava muito sonolento, sendo trocado para o Arcoxia (tomou 7 dias).
Diez medicamentos mas comercializados (a) en Ecuador en el periodo 2011-2012 (se mencionan las marcas registradas) Productos comercializados Productos comercializados con receta medica sin receta medica 2011 2012 2011 2012 1 Lipitor Seretide Ensure Arcoxia 2 Plavix Humira Apronax Kufer Q 3 Seretide Crestor Pharmaton Complejo B 4 Crestor Nexium Pediasure Fluimucil 5 Nexium Enbrel Mesygina Mesulid 6 Seroquel Remicade Neurobion Omezzol 7 Humira Abilify Mesulid Neurobion 8 Enbrel Lantux Arcoxia Doloneurobion 9 Remicade Mabthera Aspirina Abrilar 10 Abilify Cymbalta Unasyn Mesigina Fuente: IMS 2011(20).
Voltaren and Arcoxia are just some examples of NSAIDs.
Other drugs in the coxib class include cerecoxib, sold by Pfizer under the brand name Celebrex, and etoricoxib, sold by Merck under the brand name Arcoxia.
Among the brands to be marketed were Singulair for asthma, Arcoxia for pain and inflammation of joints, and Januvia for type 2 diabetes.
Uso de medicamentos y automedicacion Medicamento Total (%) Automedicado (%) Aspirina 2 (2,3%) 2 (2,5%) Acetaminofen 21 (24,1%) 17 (21,5%) Diclofenac 2 (2,3%) 2 (2,5%) Ibuprofeno 34 (39,1%) 32 (40,5%) Arcoxia 1 (1,1%) 0 (0%) Celebrex 1 (1,1%) 1 (1,3%) Dipirona 4 (4,6%) 3 (3,8%) Otros (buscapina) 22 (25,3%) 22 (27,8%) Total 87 79 Tabla 3.
Although the law requires that in order to be marketed, a drug must simply be shown to be safe and effective, in denying approval of Merck's new drug, Arcoxia, a COX-2 inhibitor for the relief of arthritis pain, the FDA said that Arcoxia needed to be shown to be superior to existing drugs to merit approval.
s (Whitehouse Station NJ) painkiller Arcoxia needs new warnings of heart risks when treating inflammation of the spine and joints, the European Medicines Agency recommended.
We pursued FDA approval of Arcoxia because we strongly believe that new medicines are needed for patients whose osteoarthritis pain is inadequately managed with currently available therapies.
Agrega que es probable que para iniciar el tratamiento suministremos farmacos innovadores de ultima generacion que alivian dolor e inflamacion, entre los que destaca Arcoxia (etoricoxib), que cuenta con doble poder analgesico y antiinflamatorio por 24 horas con una sola dosis y que, a diferencia de tradicionales, su uso constante no dana el estomago.
For instance, Merck's new COX-2 inhibitor, Arcoxia, is available only outside the United States.